Floatz logo

Axitinib

Neuroendocrine Tumors

Grupo Espanol de Tumores NeuroendocrinosSmall moleculePhase 2/3Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
73/ 100

Competitive context

62 Active assets in the Neuroendocrine Tumors cohort.

Asset / SponsorPhaseRating
Irinotecan
First Affiliated Hospital Xi'an Jiaotong University
Phase 4BB
Eloxatin
ITM Solucin GmbH
Phase 3BB
Bms-907351
Fox Chase Cancer Center
Phase 3BB
FLUOROURACILUM
ITM Solucin GmbH
Phase 3BB
Pasireotide
RECORDATI GROUP
Phase 4BB

View all 50 →

Same molecule, other indications

Axitinib is also rated in:

kidney neoplasmDormant
BB
Indicative ·
69 / 100
View asset →
Kidney NeoplasmDormant
BB
Indicative ·
67 / 100
View asset →
renal cell carcinomaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →